Company Announcement / Press release Archives - Page 11 of 17

Number of shares and votes in Xspray

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma has changed as a result of shares being registered due to the directed share issue which was carried out in October 2020. Through the direct share issue, carried out in October 2020, the number of outstanding shares […]

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2021

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting in 2021. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 14 May 2020, consists of: Gillis Cullin, appointed by Östersjöstiftelsen Johan Gyllenswärd, appointed by Ribbskottet AB Caroline Sjösten, […]

Xspray Pharma Has Carried Out a Directed Share Issue Raising Gross Proceeds of Approximately SEK 265 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on the authorisation […]

Xspray Pharma Contemplates a Directed Share Issue

Number of shares and votes in Xspray

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of the exercise of warrants under the company's incentive programs. Through the exercise of warrants under the company's incentive program, the number of outstanding shares and votes has increased by 219,632 […]

Xspray announces positive preliminary results from the study for its lead product candidate HyNap-Dasa

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces preliminary results from the second out of two bioequivalence studies in healthy volunteers with its lead product candidate HyNap-Dasa. The study fulfilled statistical and formal bioequivalence requirements for HyNap-Dasa compared to the reference product Sprycel. The study was conducted in healthy volunteers under fed conditions. “I am […]

Michael Wolff Jensen will not stand for re-election as Chairman of Xspray Pharma AB

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the Chairman of the Board, Michael Wolff Jensen, has informed the company that he will not stand for re-election at the 2021 Annual General Meeting (AGM). Michael Wolff Jensen has been Chairman of Xspray Pharma’s Board of Directors since 2013, and will stay as Chairman until […]

Number of shares and votes in Xspray

Xspray announces positive stability data on HyNap-Dasa tablets

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces six months data from its stability study with HyNap-Dasa tablets manufactured in commercial scale. Six months stability data on commercially manufactured HyNap-Dasa demonstrates that the tablets complies with specifications and that they can be used in an upcoming ANDA filing. In February 2020 stability studies were initiated […]

Warrant holders exercise all warrants within the framework of incentive program

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the CEO Per Andersson and other warrant holders have chosen to make full use of the opportunity to subscribe for shares in Xspray by fully exercising their respective number of warrants in the warrant program LTIP 2017/2020. At the same time, Chairman of the Board Michael […]